Editas Medicine, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EDIT Nasdaq 2836 www.editasmedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Editas Medicine, Inc.

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Mar 10th, 2026 9:09 am
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum - Mar 10th, 2026 5:30 am
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates - Mar 9th, 2026 6:15 am
Editas: Q4 Earnings Snapshot - Mar 9th, 2026 5:11 am
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - Mar 9th, 2026 5:00 am
Editas Medicine to Participate in Upcoming Investor Conferences - Feb 23rd, 2026 7:00 am
Companies Like Editas Medicine (NASDAQ:EDIT) Could Be Quite Risky - Feb 9th, 2026 4:03 am
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? - Dec 10th, 2025 9:30 am
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline - Nov 25th, 2025 8:43 am
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Nov 20th, 2025 9:38 am
Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies - Nov 20th, 2025 6:00 am
Top 3 Genomics Stocks to Consider for Your Portfolio - Nov 18th, 2025 6:48 am
Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates - Nov 13th, 2025 4:19 am
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y - Nov 11th, 2025 8:37 am
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates - Nov 10th, 2025 6:25 am
Editas: Q3 Earnings Snapshot - Nov 10th, 2025 5:24 am
Editas Medicine Announces Third Quarter 2025 Results and Business Updates - Nov 10th, 2025 5:00 am
Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates - Nov 7th, 2025 5:10 am
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2025 4:10 pm
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - Nov 3rd, 2025 7:00 am